Cargando…

Lymphatic Dysfunction as a Novel Therapeutic Target in Nonalcoholic Steatohepatitis

Detalles Bibliográficos
Autores principales:	Jeong, Jain, Iwakiri, Yasuko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846486/ https://www.ncbi.nlm.nih.gov/pubmed/33220266 http://dx.doi.org/10.1016/j.jcmgh.2020.10.013

Ejemplares similares

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
por: Zhang, Yao, et al.
Publicado: (2022)

Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0
por: Vairetti, Mariapia, et al.
Publicado: (2022)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Nature or Nurture? The Answer Is “Both” in Nonalcoholic Steatohepatitis
por: Carr, Rotonya M.
Publicado: (2020)

Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey
por: Alves, Venancio Avancini Ferreira, et al.
Publicado: (2016)

Matrix Gla Protein, a New Target Fighting Against Fibrosis of Nonalcoholic Steatohepatitis?
por: Hinz, Kaitlyn, et al.
Publicado: (2023)

Glutamine Breakdown as a Potential Metabolic Biomarker for Nonalcoholic Steatohepatitis
por: Garcia Whitlock, Anna E., et al.
Publicado: (2020)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

Nonalcoholic steatohepatitis (NASH) is associated with cardiac remodeling and dysfunction
por: Simon, Tracey G., et al.
Publicado: (2017)

The Role of Natural Killer Cells in Nonalcoholic Steatohepatitis: An Ongoing Debate
por: Jiang, Xiaojun, et al.
Publicado: (2021)

The lymphatic system in alcohol-associated liver disease
por: Kondo, Reiichiro, et al.
Publicado: (2020)

Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis
por: Chung, Goh Eun, et al.
Publicado: (2013)

Targeting of Secretory Proteins as a Therapeutic Strategy for Treatment of Nonalcoholic Steatohepatitis (NASH)
por: Kim, Kyeongjin, et al.
Publicado: (2020)

Lamin Deficiency in the Liver Sets the Stage for Nonalcoholic Steatohepatitis Development in Males
por: Hendrikx, Tim, et al.
Publicado: (2017)

Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches
por: Kim, Kook Hwan, et al.
Publicado: (2018)

Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
por: Yang, Rui-Xu, et al.
Publicado: (2019)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk
por: Al-hamoudi, Waleed, et al.
Publicado: (2020)

The Hepatic Lymphatic Vascular System: Structure, Function, Markers, and Lymphangiogenesis
por: Tanaka, Masatake, et al.
Publicado: (2016)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023)

The lymphatic vascular system in liver diseases: its role in ascites formation
por: Chung, Chuhan, et al.
Publicado: (2013)

Targeting hepatic miR-221/222 for therapeutic intervention of nonalcoholic steatohepatitis in mice
por: Jiang, Xiuli, et al.
Publicado: (2018)

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis
por: Liu, Wenli, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait
por: Pirola, Carlos J., et al.
Publicado: (2022)

Collagen Characterization in a Model of Nonalcoholic Steatohepatitis with Fibrosis; A Call for Development of Targeted Therapeutics
por: Pellicano, Anthony J., et al.
Publicado: (2021)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma
por: Nishina, Sohji, et al.
Publicado: (2022)

Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Lee, Chanbin, et al.
Publicado: (2019)

Impact of a Novel Digital Therapeutics System on Nonalcoholic Steatohepatitis: The NASH App Clinical Trial
por: Sato, Masaya, et al.
Publicado: (2023)

Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis
por: Xiong, Fei, et al.
Publicado: (2022)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options
por: Milic, Sandra, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1gqiap86ao05vrt892f7oqphk7